Adherence to Antihypertensive Treatment and the Blood Pressure-Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial

Circulation

Volumn 134, Issue 12, 2016, Pages 847-857

  Azizi, Michel ^a,b,c   Pereira, Helena ^b,c   Hamdidouche, Idir ^b   Gosse, Philippe ^d   Monge, Matthieu ^e   Bobrie, Guillaume ^b   Delsart, Pascal ^f   Mounier Véhier, Claire ^f   Courand, Pierre Yves ^g   Lantelme, Pierre ^g   Denolle, Thierry ^h   Dourmap Collas, Caroline ⁱ   Girerd, Xavier ^j   Michel Halimi, Jean ^k   Zannad, Faiez ^l   Ormezzano, Olivier ^m   Vaïsse, Bernard ⁿ   Herpin, Daniel ^o   Ribstein, Jean ^p   Chamontin, Bernard ^q   Mourad, Jean Jacques ^r   Ferrari, Emile ^s   Plouin, Pierre François ^a   Jullien, Vincent ^a,b,t   Sapoval, Marc ^a,b   Chatellier, Gilles ^a,b,c   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

^d HÔPITAL SAINT ANDRÉ   (France)

^e INSTITUT MUTUALISTE MONTSOURIS   (France)

^f UNIV LILLE   (France)

^g Department of Hepatology   (France)

^h Arthur Gardiner Hospital   (France)

ⁱ RENNES UNIVERSITY HOSPITAL   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k CHU BRETONNEAU   (France)

^l CHU NANCY BRABOIS   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ TIMONE HOSPITAL   (France)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p MONTPELLIER UNIVERSITY HOSPITAL   (France)

^q CHU RANGUEIL   (France)

^r AVICENNE HOSPITAL   (France)

^s PASTEUR HOSPITAL   (France)

^t CNRS   (France)

more..

Author keywords

ablation techniques; hypertension; kidney; medications; nervous system; sympathetic nervous system

Indexed keywords

AMLODIPINE; BISOPROLOL; INDAPAMIDE; IRBESARTAN; PRAZOSIN; RAMIPRIL; RILMENIDINE; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT REFUSAL; URINE SAMPLING; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; DRUG EFFECTS; FEMALE; HYPERTENSION; KIDNEY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84986208142     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022922     Document Type: Article

References (34)

1. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G; Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957-1965. doi: 10.1016/S0140-6736(14)61942-5.
2. Korb-Savoldelli V, Gillaizeau F, Pouchot J, Lenain E, Postel-Vinay N, Plouin PF, Durieux P, Sabatier B. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults. J Clin Hypertens (Greenwich). 2012;14:429-434. doi: 10.1111/j.1751-7176.2012.00634.x.
3. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62:218-225. doi: 10.1161/HYPERTENSIONAHA. 113.00687.
4. Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, Morisky DE, Halm EA, Vongpatanasin W. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens. 2015;9:420-426.e2. doi: 10.1016/j.jash.2015.04.004.
5. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774. doi: 10.1097/HJH.0b013e32835e2286.
6. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of non-adherence to antihypertensive treatment revealed by highperformance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861. doi: 10.1136/heartjnl-2013-305063.
7. Strauch B, Petrák O, Zelinka T, Rosa J, Somloóvá Z, Indra T, Chytil L, Marešová V, Kurcová I, Holaj R, Wichterle D, Widimský J Jr. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455-2461. doi: 10.1097/HJH.0b013e3283652c61.
8. Azizi M, Ménard J, Peyrard S, Lièvre M, Marre M, Chatellier G. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. Diabetes Care. 2006;29:1331-1336. doi: 10.2337/dc06-0255.
9. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219-227. doi: 10.1093/eurheartj/ehu441.
10. Mahfoud F, Lüscher TF. Renal denervation: symply trapped by complexity? Eur Heart J. 2015;36:199-202. doi: 10.1093/eurheartj/ehu450.
11. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
12. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. doi: 10.1056/NEJMoa1402670.
13. Rosa J, Widimský P, Toušek P, Petrák O, ?urila K, Waldauf P, Bedná? F, Zelinka T, Holaj R, Štrauch B, Šomloóvá Z, Táborský M, Václavík J, Kociánová E, Branny M, Nykl I, Jiravský O, Widimský J Jr. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65:407-413. doi: 10.1161/HYPERTENSIONAHA. 114.04019.
14. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65:1202-1208. doi: 10.1161/HYPERTENSIONAHA.115.05283.
15. Fadl Elmula FE, Jin Y, Yang WY, Thijs L, Lu YC, Larstorp AC, Persu A, Sapoval M, Rosa J, Widimský P, Jacobs L, Renkin J, Petrák O, Chatellier G, Shimada K, Widimský J, Kario K, Azizi M, Kjeldsen SE, Staessen JA; European Network Coordinating Research On Renal Denervation (ENCOReD) Consortium. Meta-analysis of randomized controlled trials of renal denervation in treatmentresistant hypertension. Blood Press. 2015;24:263-274. doi: 10.3109/08037051.2015.1058595.
16. Kjeldsen SE, Persu A, Azizi M. Design of renal denervation studies not confounded by antihypertensive drugs. J Am Soc Hypertens. 2015;9:337-340. doi: 10.1016/j.jash.2015.02.015.
17. Yang WY, Staessen JA. Hypertension: Renal denervation-promising data from the DENERHTN trial. Nat Rev Nephrol. 2015;11:258-260. doi: 10.1038/nrneph.2015.28.
18. Esler M. Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med. 2015;25:107-115. doi: 10.1016/j.tcm.2014.09.014.
19. Persu A, Kjeldsen S, Staessen JA, Azizi M. Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep. 2016;18:6. doi: 10.1007/s11906-015-0610-9.
20. Sedgwick P, Greenwood N. Understanding the Hawthorne effect. BMJ. 2015;351:h4672.
21. Beaussier H, Boutouyrie P, Bobrie G, Frank M, Laurent S, Coudoré F, Azizi M. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens. 2015;33:2526-2533. doi: 10.1097/HJH.0000000000000737.
22. Patel P, Gupta PK, White CM, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30:368-373. doi: 10.1038/jhh.2015.103.
23. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. doi: 10.1093/eurheartj/eht151.
24. Kjeldsen SE, Julius S, Dahlöf B, Weber MA. Physician (investigator) inertia in apparent treatment-resistant hypertension-insights from large randomized clinical trials. Lennart Hansson Memorial Lecture. Blood Press. 2015;24:1-6. doi: 10.3109/08037051.2014.946787.
25. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatmentresistant hypertension. Hypertension. 2014;63:991-999. doi: 10.1161/HYPERTENSIONAHA.114.03246.
26. Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Böhm M, Mahfoud F. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104:1097-1105. doi: 10.1007/s00392-015-0905-5.
27. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-2879.
28. Hering D. Renal denervation superior to drug therapy in hypertension. Lancet. 2015;385:1922-1924. doi: 10.1016/S0140-6736(14)62050-X.
29. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315. doi: 10.1016/S0140-6736(01)06411-X.
30. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-629. doi: 10.1016/S0140-6736(13)62192-3.
31. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65:1314-1321. doi: 10.1016/j.jacc.2015.01.037.
32. Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-2227. doi: 10.1093/eurheartj/ehv192.
33. Laffin LJ, Bakris GL. Renal Denervation: a Field in Flux. Curr Hypertens Rep. 2016;18:56. doi: 10.1007/s11906-016-0666-1.
34. Berra E, Azizi M, Capron A, Høieggen A, Rabbia F, Kjeldsen SE, Staessen JA, Wallemacq P, Persu A. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297-306. doi: 10.1161/HYPERTENSIONAHA.116.07464.